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SUMMARY
 
Annexin V has an important role in the regulation of apoptosis and antibodies directed against it have
been shown to lead to apoptosis of vascular endothelial cells. To evaluate the role of anti-annexin V anti-
bodies (AA5A) in Takayasu’s arteritis (TA), we investigated these antibodies in the sera of 66 TA
patients, 50 healthy controls and in the follow-up sera of 12 active TA patients by enzyme-linked immu-
nosorbent assay. The AA5A-positive patients were analysed further for the presence of anti-endothelial
cell antibodies (AECA) and anticardiolipin antibodies (ACLA) to determine the relationship of AA5A
with these autoantibodies. AA5A were observed in 36% (24/66) of the patients 
 
versus
 
 6% (3/50) of the
controls (
 
P
 
 
 
<
 
 0·001) and in 53% (19/36) of patients with active TA 
 
versus
 
 17% (5/30) of those with inac-
tive disease (
 
P
 
 
 
<
 
 0·01). Levels of AA5A were also observed to be significantly higher in patients with TA
compared to controls (0·557 
 
±
 
 0·362 
 
versus
 
 0·259 
 
±
 
 0·069; 
 
P
 
 
 
<
 
 0·0001) and in patients with active disease
compared to those with inactive disease (0·700 
 
±
 
 0·403 
 
versus
 
 0·385 
 
±
 
 0·205; 
 
P
 
 
 
<
 
 0·0001). In the follow-
up study, 6/12 patients who became inactive during follow-up also showed normalization of AA5A lev-
els. AECA and ACLA were detected in 54% (13/24) and 12% (3/24) of the AA5A-positive patients,
respectively. Our results show that a significant proportion of TA patients have AA5A, which exhibit an
association with AECA and because they have a correlation with disease activity thus appear to be
involved in the disease pathogenesis.
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INTRODUCTION
 
Takayasu’s arteritis (TA) is an idiopathic chronic inflammatory
pan-arteritis characterized by stenosis or aneurysmal dilation of
large elastic arteries, mainly the aorta and its major branches,
including pulmonary and coronary arteries. It is the most common
vasculitic disorder in India and the third most common vasculitis
in the paediatric age group worldwide [1,2].
Immune-mediated damage of vascular endothelial cells
(ECs) is the initial event in the pathogenesis of TA [3,4]. The
presence of apoptotic ECs in vascular lesions and in the circula-
tion of allied vasculopathies suggests that apoptosis may be one
of the major pathways of inflammatory damage of ECs [5]. A
fundamental feature of ECs and other cell types undergoing
apoptosis is the externalization of plasma membrane phosphati-
dylserine (PS) [6]. Annexin V, which is found abundantly in ECs
and has a well-characterized Ca
 
2
 
+
 
-dependent natural binding
affinity to anionic phospholipids such as PS, plays an important
role in the regulation of proinflammatory and procoagulant
activities of apoptotic cells by shielding their exposed PS [7,8].
Furthermore, it may also be important in maintaining the integ-
rity of early apoptotic cells and in the regulation of apoptotic
process itself [9–11]. A dysregulation in the expression or activity
of this protein 
 
in vivo
 
 may therefore have an important role in
vascular damage.
Recently, anti-annexin V antibodies (AA5A) have been
observed to cause apoptosis of cultured ECs 
 
in vitro
 
 [12,13]
 
.
 
These antibodies are reported commonly in clinical conditions,
which also contain anti-endothelial cell antibodies (AECA) and
antibodies to cardiolipin (ACLA) or other phospholipids [14–17].
However, a relationship of AA5A with these autoantibodies is
not yet known. Because AECA and ACLA are observed fre-
quently in patients with TA (18), we hypothesized that AA5A,
which may have an important role in vascular damage, are quite
likely to be present in the disease.
We thus undertook this study to investigate the prevalence of
AA5A and to determine the relationship of these antibodies with
disease activity as well as with AECA and ACLA in patients with
TA.
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SUBJECTS AND METHODS
 
Subjects
 
Sixty-six patients with TA (27 males, 39 females; mean age
27 
 
±
 
 11 years; range: 12–45 years) were included in the study. The
diagnosis of TA was established on the basis of clinical, laboratory
and angiographic findings of the disease. All patients fulfilled at
least three of the American College of Rheumatology Criteria
1990 for TA [19]. These include (i) bruits over subclavian arteries
or aorta, (ii) decrease or absent brachial artery pulse and (iii) sys-
tolic blood pressure difference of 
 
>
 
10 mmHg between the arms.
Finally, in each case the diagnosis of TA was confirmed by angiog-
raphy and all the patients were found to have angiographically
proven disease. Disease activity of the patients was determined by
the following criteria: (i) systemic features such as fever, arthral-
gias, myalgias or weight loss of unknown cause; (ii) carotidynia
(painful arteries); (iii) elevated erythrocyte sedimentation rate
(ESR) (
 
>
 
30 mm/ h) and (iv) elevated C-reactive protein (CRP)
(
 
>
 
0·6 mg/dL) levels. A patient was considered to be in the active
stage if two or more of these criteria were present along with
other features of the disease [18]. Accordingly, 36 patients had an
active disease and 30 had an inactive disease. Control subjects
consisted of 50 age- and sex-matched healthy individuals. Most of
the controls were individuals residing in the same area as the
patients, while some were paramedical staff of the Institute. After
obtaining informed consent, 5 ml of venous blood was obtained
from each individual and isolated serum was stored at –80
 
∞
 
C until
analysis.
Patients with active disease were put on immunosuppressive
therapy consisting of prednisolone and azathioprine, which were
given for 2 years with tapering of the doses as the disease became
less active. Twelve patients with active disease, who were positive
for AA5A and visited our clinic regularly, were followed-up pro-
spectively to determine a relationship between levels of these
antibodies and remission of disease activity.
This study was approved by the Institutional Ethics Commit-
tee of Sanjay Gandhi Post-Graduate Institute of Medical Sciences
(SGPGIMS), Lucknow.
 
Detection of anti annexin V antibodies (AA5A)
 
AA5A were detected by enzyme-linked immunosorbent assay
(ELISA) using recombinant human annexin V as antigen accord-
ing to a validated procedure described previously, with minor
modifications [20].
Briefly, gamma-irradiated 96-well flat-bottomed plates (Nunc,
Roskilde, Denmark) were coated with 0·5 
 
m
 
g/well of purified
recombinant annexin V (BD Phammingen, Mountain View, CA,
USA) in a final volume of 100 
 
m
 
l of carbonate–bicarbonate buffer
(0·05 
 
M
 
, pH 9·6) and incubated at 4
 
∞
 
C for 24 h. Following this and
each of the subsequent incubation steps, washing was performed
with phosphate buffered saline (PBS, pH 7·4) containing 0·2%
bovine serum albumin (BSA) and 0·05% Tween-20 (wash buffer).
The non-specific binding sites of each well were blocked by add-
ing 250 
 
m
 
l of PBS containing 3% BSA and incubating the plate at
37
 
∞
 
C for 2 h. Test and reference sera diluted 1 : 300 with wash
buffer were added 100 
 
m
 
l/well in duplicate, with one set of dupli-
cate wells containing wash buffer alone (antibody free) and the
plates were incubated for 2 h at 37
 
∞
 
C. The bound antibodies were
detected by incubating 100 
 
m
 
l/well of 1 : 3000 diluted 
 
g
 
 chain-
specific goat antihuman IgG-alkaline phosphatase (Sigma, St
Louis, MO, USA). The colour reaction was developed by adding
100 
 
m
 
l/well of 1 mg/ml of p-nitropheny1 phosphate (Sigma) in
diethanolamine buffer (pH 9·8) and the absorbance was read in
an automated ELISA reader (Tecan Spectra, Austria) at 405 
 
h
 
m.
Two positive and negative sera were included as standards in
each run. Each plate was read when the optical density (OD) of
positive controls reached 1·0–1·2 (always within 35 min). The
blank value of the plate was subtracted from the sample value to
obtain specific OD for each sample. The cut-off value for deter-
mining a sample to be positive, was taken as mean 
 
±
 
 2 s.d. of the
OD of the normal controls. The interassay coefficient of variation
was 8·5%.
 
Assay for AECA and ACLA
 
To determine a relationship of AA5A with AECA and ACLA,
the patient sera, which were found to be positive for AA5A, were
tested for the presence of each of these antibodies using a stan-
dardized ELISA as described previously [18].
In the AECA assay each sample was run in triplicate and
results were expressed as mean optical density (OD) values. The
cut-off for the positivity of these antibodies was taken as mean 
 
±
 
s.d. of 25 normal healthy controls run in parallel.
All samples for the detection of ACLA were run in duplicate
and results were expressed as IgG phospholipid units (GPLU)
calculated as per standard samples used in the assay. A sample
was considered to be ACLA positive if its GPLU was 
 
≥
 
10.
 
Statistical analysis
 
Statistical analysis was performed using 
 
Z
 
 statistics for parametric
data and Man–Whitney 
 
U
 
-test for non-parametric data. A 
 
P
 
-
value 
 
<
 
 0·05 was considered to be statistically significant.
 
RESULTS
 
Prevalence of AA5A
 
AA5A were observed in 36% (24/66) of patients with TA and in
6% (3/50) of controls (
 
P
 
 
 
<
 
 0·001). Their prevalence in patients
with active TA and those with an inactive disease was 53% (19/36)
and 17% (5/30), respectively (
 
P
 
 
 
<
 
 0·01).
The levels of AA5A were significantly higher in patients com-
pared to controls (0·557 
 
±
 
 0·362 
 
versus
 
 0·259 
 
±
 
 0·069; 
 
P
 
 
 
<
 
 0·0001)
and in patients with active disease compared to those with
inactive disease (0·700 
 
±
 
 0·403 
 
versus
 
 0·385 
 
±
 
 0·205; 
 
P
 
 
 
<
 
 0·0001)
(Fig. 1).
 
Relationship of AA5A with disease activity
 
Of the 12 patient in whom a follow-up study was performed, six
patients who became inactive also exhibited normalization of
AA5A levels. The median follow-up period of these patients was
18 months (range: 12–24 months) (Fig. 2a). The remaining six
patients who remained active during follow-up also continued to
have elevated levels of AA5A, although the levels in two of these
patients declined significantly but did not normalize till the last
follow-up. The median follow-up period of these patients was
19 months (range: 16–24 months) (Fig. 2b).
The levels of these autoantibodies in patients in remission and
in those who remained active on follow-up also correlated posi-
tively with CRP and ESR, the laboratory measures used to assess
disease activity in the study. In patients in remission, however,
CRP was raised in two cases and ESR had upper borderline val-
ues in another two cases, but they were found otherwise to be
inactive. Similarly, two follow-up patients, who had remained
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active on follow-up, had normal ESR but had other features of an
active disease (Table 1).
 
Relationship of AA5A with AECA and ACLA
 
AECA and ACLA were detected in 54% (13/24) and 12% (3/24)
of AA5A positive TA patients, respectively.
 
DISCUSSION
 
Our study shows that AA5A are present in a significant propor-
tion of patients with TA, particularly those with an active stage of
the disease. To the best of our knowledge, this is the first evidence
for the presence of these antibodies in a vasculitic entity.
 
Fig. 1.
 
 Box plot showing levels of AA5A in Takayasu’s arteritis (TA)
patients (
 
n
 
 
 
=
 
 66), healthy controls (
 
n
 
 
 
=
 
 50), patients with active TA
(
 
n
 
 
 
=
 
 36) and patients with inactive TA (
 
n
 
 
 
=
 
 30). The box includes obser-
vations from the 25th to the 75th percentile. The horizontal line within
the box represents the median value. The upper and lower lines outside
the box represent the highest and lowest value, respectively. The circles
and asterisks represent outliers and extreme OD values of AA5A,
respectively, in different subject groups. The levels of AA5A were signif-
icantly higher in patients with TA compared to controls (
 
P
 
 
 
<
 
 0·0001) and
in patients with active TA compared to those with inactive TA
(
 
P
 
 
 
<
 
 0·0001).
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Fig. 2.
 
 Relationship of AA5A levels with disease activity in 12 prospec-
tively followed-up active TA patients. (a) Six patients who underwent
remission (median follow-up period: 18 months; range: 12–24 months)
showed normalization of the levels of these antibodies. (b) The remaining
six patients who continued to show disease activity (median follow-up
period: 19 months; range: 16–24 months) continued to have elevated levels
of these antibodies. Each line represents data of an individual patient. The
straight line represents the cut-off OD value (0·397), above which a sample
was taken as positive for AA5A.
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Table 1.
 
 Relationship of anti-annexin V antibodies (AA5A) with laboratory measures of disease activity: C-reactive protein (CRP; normal value: 
 
<
 
0·6 mg/
dl) and erythrocyte sedimentation rate (ESR; normal value: 
 
<
 
30 mm/h) in 12 active Takayasu’s arteritis (TA) patients treated with immunosuppressive 
therapy (the cut-off value for AA5A positivity: 0·397; calculated as mean 
 
±
 
 2 s.d. of controls)
Patient
Pretreatment
AA5A levels
(OD values)
On last follow-up
AA5A levels (OD values) CRP (mg/dl) ESR (mm/h) Disease activity
Follow-up period
(months)
1 1·596 0·301
 
<
 
0·5 12 Inactive 24
2 0·951 0·282 0·9 20 Inactive 22
3 0·893 0·325 1·2 22 Inactive 12
4 0·889 0·232
 
<
 
0·5 30 Inactive 20
5 0·750 0·217
 
<
 
0·5 18 Inactive 16
6 0·574 0·269
 
<
 
0·5 30 Inactive 12
7 1·309 0·626 5·5 16 Active 24
8 1·252 1·222 3·8 35 Active 18
9 0·955 1·022 1·5 42 Active 16
10 0·896 0·878 2·7 10 Active 20
11 0·870 1·379 1·3 55 Active 24
12 0·743 0·511 0·8 36 Active 18
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AA5A are newly identified autoantibodies demonstrated for
the first time by Matsuda 
 
et al
 
. [21] in patients with habitual fetal
loss or pre-eclampsia. Since then they have been described
increasingly in several systemic autoimmune disorders, including
systemic lupus erythematosus (SLE) [16,17,22,23], anti-phospho-
lipid syndrome (APS) [23–25], fetal loss [26,27], rheumatoid
arthritis (RA) [20,28] and scleroderma [29]. More recently, raised
levels of AA5A have been reported in two young female patients
with cerebrovascular disease (CVD) and pregnancy complica-
tions, but without any clinical manifestation of a systemic autoim-
mune disease or major thrombotic risk factor [30]. In these
diseases the prevalence of AA5A is reported to be 18–30% and a
relationship of these antibodies with disease activity has been
studied only in RA, with contradictory observations by two sep-
arate author groups [20,28]. Dubois 
 
et al
 
. showed a strong associ-
ation of AA5A levels with RA disease activity [28], while
Rodriguez-Garcia 
 
et al
 
. found such an association not significant
[20]. We have observed an overall prevalence of AA5A in TA to
be 36% and a significantly higher prevalence and levels of these
antibodies in patients with active disease than in those with inac-
tive disease showing an association of AA5A with active TA. To
delineate further this relationship in the disease, we investigated
AA5A in follow-up patients who initially had active disease as
well as elevated levels of these antibodies. Our results, showing
normalization of AA5A in patients who become inactive and
their persistent elevation in those who remained active on follow-
up, suggest further a relationship of these antibodies with disease
activity in TA.
Almost all the AA5A associated diseases described above,
including TA, frequently contain AECA and ACLA [14,18,31].
Furthermore, like AA5A, some of the AECA possess the capacity
to induce apoptosis of ECs [32] and ACLA are also reported to
have an association with vascular injury [33]. However, whether
AA5A have a relationship with these autoantibodies has not yet
been explored. In the present study, we have observed the pres-
ence of AECA in a substantial proportion (54%) of AA5A-
positive patients, suggesting that annexin V might be one of the
antigenic targets of these autoantibodies. In view of this co-
existence of AA5A and AECA in TA, it is possible that the endot-
helial apoptosis-inducing capacity of AECA may be restricted to
its fraction of endothelial–annexin V-specific antibodies which
may have a direct pathogenic role, at least in this disease. Despite
this association, AA5A 
 
per se
 
 do not appear to be a subset of
AECA, as in addition to ECs annexin V is present in a variety of
cell types and they may also recognize extracellular annexin V
present in the circulation. To the best of our knowledge, this is the
first study demonstrating the co-existence of AA5A and AECA in
a disease. We also evaluated the relationship of these antibodies
with ACLA, but in contrast to AECA we did not observe an asso-
ciation between AA5A and ACLA in TA. Similarly, no ACLA are
found in most of the AA5A-positive patients with scleroderma
[29] and neither ACLA nor other tested antiphospholipid anti-
bodies were detected in two young patients with CVD who had
persistently increased levels of AA5A [30]. AA5A present in
patients with SLE have been reported to possess ACLA proper-
ties, indicating that both of these may be closely related autoan-
tibodies [15]. However, it has been shown recently in SLE that
removal of antiphospholipid activity using cardiolipin and other
phospholipid liposomes had no effect on anti-annexin activity of
the serum IgG fraction of SLE sera, also suggesting no association
between these antibodies in this disease [13]. Our observations in
TA, together with these findings, suggest that AA5A are different
from ACLA and probably from AECA as well and constitute a
distinct group of autoantibodies. The existence of autoantibodies
to other members of the annexin family, such as annexin I, -IV, VI
and XI in different autoimmune diseases, further supports that
AA5A is a separate group of autoantibodies [23,28,34,35].
The mechanism underlying the generation of AA5A is not
known. It can be speculated that conditions associated with
increased PS externalization in ECs, such as their persistent acti-
vation or apoptosis, are accompanied by increased release of
annexin V and its binding to exposed PS. This suprathreshold sur-
face expression of predominantly intracellular annexin V or
expression of some cryptic or new antigenic epitopes in the native
protein due to its binding to PS triggers the formation of these
antibodies. Demonstration of activated/apoptotic ECs in lesions
and/or in the circulation of different vasculopathies [5,36] and
hyperexpression of annexin V in large-vessel endothelium of
hypertensive pigs, and of annexin I and II in the diseased arteries
of TA patients, together lend support to this hypothesis [37,38].
The pathogenic role of AA5A is not well defined. Because
AA5A have been observed predominantly in thrombotic vascul-
opathies such as SLE and APS, most of the studies have impli-
cated these antibodies in the induction of thrombosis [17,24,25].
However, they may have a role in inflammatory tissue damage by
blocking or modulating different biological functions of annexin
V, including regulation of apoptosis [10,11], PS-mediated inflam-
mation [8,9] and calcium signalling [39]. In addition, AA5A can
also play an important role in the propagation and amplification
of the autoimmune response to apoptotic ECs by inhibiting or
altering their physiological clearance by scavenger cells [40]. A
direct pathogenic role of AA5A has been posited. Recently, these
antibodies have been shown to cause apoptosis of cultured vas-
cular ECs 
 
in vitro
 
 [12,13], necrosis of placental trophoblasts in a
mouse model [41] and inhibition of gonadotrophin secretion from
and apoptosis of human placental trophoblasts [42]. These find-
ings, and the association of AA5A with digital ischaemia in
scleroderma [29], together suggest an important role of these anti-
bodies in vascular damage. In the present study a significantly
higher association of AA5A with active disease and their normal-
ization in patients, who underwent remission on follow-up, point
towards an involvement of these antibodies in the pathogenesis of
TA. However, a precise role of these antibodies in the disease is
not clear at present and remains to be seen.
We thus conclude that a significant proportion of TA patients
have AA5A which exhibit an association with AECA and
because they have a correlation with disease activity, thus appear
to have a pathogenic role in the disease. Further studies on fac-
tor(s) triggering the formation of AA5A, their pathogenic mech-
anism(s) and reactivity to other annexins will be important to
understand the role of these antibodies in the pathogenesis of TA
and other related vasculopathies.
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